Regulatory News:
NANOBIOTIX (Euronext: NANO ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces the transfer of its shares from compartment C to compartment B of the regulated market of Euronext in Paris with effect as from January 28, 2015, thanks to its stock market capitalization increase performances during 2014.
Compartment B groups together listed companies with a stock market capitalization of between 150 million and 1 billion euros. For the record, the average market capitalization of Nanobiotix over the last 60 trading days in 2014 was 249 million euros.
This transfer has no impact on the inclusion of Nanobiotix shares to NYSE Euronext indexes.
Laurent Levy, CEO of Nanobiotix comments: Following our admission to the SRD label in December, we are proud to announce the transfer of our shares from compartment C to compartment B of the regulated market of Euronext in Paris. This transfer rewards the dynamism and stock market performance of Nanobiotix during 2014. This operation and the strong increase of Nanobiotix shares liquidity with more than 1 billion 300 million euros traded this year, should improve the visibility of Nanobiotix to the international financial and industrial communities.
Compartment transfers were officially announced to market members by means of a notice to the market from Euronext on January 26, with an effective date of January 28, 2015.
Next financial press release: revenue for the 4thquarter of 2014 by February 27, 2015
About NANOBIOTIX: http://www.nanobiotix.com/fr
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The companys first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers including Soft Tissue Sarcoma, Breast Cancer, Liver Cancer, Head and Neck Cancer, Glioblastoma, Prostate Cancer, etc., via multiple routes of administration.
Go here to read the rest:
Nanobiotix Shares Transferred from Compartment C to Compartment B of the Regulated Market of Euronext in Paris